LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins
Background: Coronary heart disease (CHD) is a leading cause of death globally. Although
therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and …
therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and …
[PDF][PDF] LPA Variants are Associated with Residual Cardiovascular Risk in Patients Receiving Statins
WQ Wei - researchgate.net
Background—Coronary heart disease (CHD) is a leading cause of death globally. Although
therapy with HMG-CoA reductase inhibitors (statins) decreases circulating levels of low …
therapy with HMG-CoA reductase inhibitors (statins) decreases circulating levels of low …
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins
WQ Wei - Circulation, 2018 - Am Heart Assoc
BACKGROUND: Coronary heart disease (CHD) is a leading cause of death globally.
Although therapy with statins decreases circulating levels of low-density lipoprotein …
Although therapy with statins decreases circulating levels of low-density lipoprotein …
LPA variants are associated with residual cardiovascular risk in patients receiving statins
WQ Wei, X Li, Q Feng, M Kubo, IJ Kullo… - …, 2018 - mayoclinic.elsevierpure.com
BACKGROUND: Coronary heart disease (CHD) is a leading cause of death globally.
Although therapy with statins decreases circulating levels of low-density lipoprotein …
Although therapy with statins decreases circulating levels of low-density lipoprotein …
[HTML][HTML] LPA variants are associated with residual cardiovascular risk in patients receiving statins
WQ Wei, X Li, Q Feng, M Kubo, IJ Kullo, PL Peissig… - Circulation, 2018 - ncbi.nlm.nih.gov
Background: Coronary heart disease (CHD) is a leading cause of death globally. Although
therapy with HMG-CoA reductase inhibitors (statins) decreases circulating levels of low …
therapy with HMG-CoA reductase inhibitors (statins) decreases circulating levels of low …
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins
WQ Wei, X Li, Q Feng, M Kubo, IJ Kullo… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Coronary heart disease (CHD) is a leading cause of death globally. Although
therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and …
therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and …
LPA variants are associated with residual cardiovascular risk in patients receiving statins
WQ Wei, X Li, Q Feng, M Kubo, IJ Kullo… - …, 2018 - scholars.northwestern.edu
BACKGROUND: Coronary heart disease (CHD) is a leading cause of death globally.
Although therapy with statins decreases circulating levels of low-density lipoprotein …
Although therapy with statins decreases circulating levels of low-density lipoprotein …
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.
WQ Wei, X Li, Q Feng, M Kubo, IJ Kullo, PL Peissig… - Circulation, 2018 - europepmc.org
Background Coronary heart disease (CHD) is a leading cause of death globally. Although
therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and …
therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and …
[PDF][PDF] LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins
WQ Wei - Circulation, 2018 - academia.edu
BACKGROUND: Coronary heart disease (CHD) is a leading cause of death globally.
Although therapy with statins decreases circulating levels of low-density lipoprotein …
Although therapy with statins decreases circulating levels of low-density lipoprotein …
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.
WQ Wei, X Li, Q Feng, M Kubo, IJ Kullo, PL Peissig… - Circulation, 2018 - jichi.ac.jp
現在, 遺伝子・蛋白・代謝産物 (genome-proteome-metabolome) を網羅的・包括的に捉える研究
分野を “オミックス “と呼ぶが, このアプローチにより疾患の病態生理・治療に新たな視点が加わり …
分野を “オミックス “と呼ぶが, このアプローチにより疾患の病態生理・治療に新たな視点が加わり …